Cargando…

A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma

Adamantinomatous craniopharyngioma (ACP) is the most common tumor of the sellar region in children. The aggressive behavior of ACP challenges the treatment for it. However, immunotherapy is rarely studied in ACP. In this research, we performed unsupervised cluster analysis on the 725 immune-related...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Feng, Cai, Xiangming, Zhu, Junhao, Yuan, Lei, Wang, Yingshuai, Tang, Chao, Cong, Zixiang, Ma, Chiyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710480/
https://www.ncbi.nlm.nih.gov/pubmed/34966342
http://dx.doi.org/10.3389/fneur.2021.704130
_version_ 1784623163242446848
author Yuan, Feng
Cai, Xiangming
Zhu, Junhao
Yuan, Lei
Wang, Yingshuai
Tang, Chao
Cong, Zixiang
Ma, Chiyuan
author_facet Yuan, Feng
Cai, Xiangming
Zhu, Junhao
Yuan, Lei
Wang, Yingshuai
Tang, Chao
Cong, Zixiang
Ma, Chiyuan
author_sort Yuan, Feng
collection PubMed
description Adamantinomatous craniopharyngioma (ACP) is the most common tumor of the sellar region in children. The aggressive behavior of ACP challenges the treatment for it. However, immunotherapy is rarely studied in ACP. In this research, we performed unsupervised cluster analysis on the 725 immune-related genes and arrays of 39 patients with ACP patients in GSE60815 and GSE94349 databases. Two novel immune subtypes were identified, namely immune resistance (IR) subtype and immunogenic (IG) subtype. Interestingly, we found that the ACPs with IG subtype (34.78%, 8/23) were more likely to respond to immunotherapy than the ACPs with IR subtype (6.25%, 1/16) via tumor immune dysfunction and exclusion (TIDE) method. Simultaneously, the enrichment analysis indicated that the differentially expressed genes (DEGs) (p < 0.01, FDR < 0.01) of the IG subtype were chiefly involved in inflammatory and immune responses. However, the DEGs of the IR subtype were mainly involved in RNA processing. Next, immune infiltration analysis revealed a higher proportion of M2 macrophage in the IG subtype than that in the IR subtype. Compared with the IR subtype, the expression levels of immune checkpoint molecules (PD1, PDL1, PDL2, TIM3, CTLA4, Galectin9, LAG3, and CD86) were significantly upregulated in the IG subtype. The ssGSEA results demonstrated that the biofunction of carcinogenesis in the IG subtype was significantly enriched, such as lymphocyte infiltration, mesenchymal phenotype, stemness maintenance, and tumorigenic cytokines, compared with the IR subtype. Finally, a WDR89 (the DEG between IG and IR subtype)-based nomogram model was constructed to predict the immune classification of ACPs with excellent performance. This predictive model provided a reliable classification assessment tool for clinicians and aids treatment decision-making in the clinic.
format Online
Article
Text
id pubmed-8710480
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87104802021-12-28 A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma Yuan, Feng Cai, Xiangming Zhu, Junhao Yuan, Lei Wang, Yingshuai Tang, Chao Cong, Zixiang Ma, Chiyuan Front Neurol Neurology Adamantinomatous craniopharyngioma (ACP) is the most common tumor of the sellar region in children. The aggressive behavior of ACP challenges the treatment for it. However, immunotherapy is rarely studied in ACP. In this research, we performed unsupervised cluster analysis on the 725 immune-related genes and arrays of 39 patients with ACP patients in GSE60815 and GSE94349 databases. Two novel immune subtypes were identified, namely immune resistance (IR) subtype and immunogenic (IG) subtype. Interestingly, we found that the ACPs with IG subtype (34.78%, 8/23) were more likely to respond to immunotherapy than the ACPs with IR subtype (6.25%, 1/16) via tumor immune dysfunction and exclusion (TIDE) method. Simultaneously, the enrichment analysis indicated that the differentially expressed genes (DEGs) (p < 0.01, FDR < 0.01) of the IG subtype were chiefly involved in inflammatory and immune responses. However, the DEGs of the IR subtype were mainly involved in RNA processing. Next, immune infiltration analysis revealed a higher proportion of M2 macrophage in the IG subtype than that in the IR subtype. Compared with the IR subtype, the expression levels of immune checkpoint molecules (PD1, PDL1, PDL2, TIM3, CTLA4, Galectin9, LAG3, and CD86) were significantly upregulated in the IG subtype. The ssGSEA results demonstrated that the biofunction of carcinogenesis in the IG subtype was significantly enriched, such as lymphocyte infiltration, mesenchymal phenotype, stemness maintenance, and tumorigenic cytokines, compared with the IR subtype. Finally, a WDR89 (the DEG between IG and IR subtype)-based nomogram model was constructed to predict the immune classification of ACPs with excellent performance. This predictive model provided a reliable classification assessment tool for clinicians and aids treatment decision-making in the clinic. Frontiers Media S.A. 2021-12-13 /pmc/articles/PMC8710480/ /pubmed/34966342 http://dx.doi.org/10.3389/fneur.2021.704130 Text en Copyright © 2021 Yuan, Cai, Zhu, Yuan, Wang, Tang, Cong and Ma. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Yuan, Feng
Cai, Xiangming
Zhu, Junhao
Yuan, Lei
Wang, Yingshuai
Tang, Chao
Cong, Zixiang
Ma, Chiyuan
A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma
title A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma
title_full A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma
title_fullStr A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma
title_full_unstemmed A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma
title_short A Novel Immune Classification for Predicting Immunotherapy Responsiveness in Patients With Adamantinomatous Craniopharyngioma
title_sort novel immune classification for predicting immunotherapy responsiveness in patients with adamantinomatous craniopharyngioma
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710480/
https://www.ncbi.nlm.nih.gov/pubmed/34966342
http://dx.doi.org/10.3389/fneur.2021.704130
work_keys_str_mv AT yuanfeng anovelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT caixiangming anovelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT zhujunhao anovelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT yuanlei anovelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT wangyingshuai anovelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT tangchao anovelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT congzixiang anovelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT machiyuan anovelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT yuanfeng novelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT caixiangming novelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT zhujunhao novelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT yuanlei novelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT wangyingshuai novelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT tangchao novelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT congzixiang novelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma
AT machiyuan novelimmuneclassificationforpredictingimmunotherapyresponsivenessinpatientswithadamantinomatouscraniopharyngioma